AbCellera Biologics Inc(ABCL) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.54 | Insider Own | 21.74% | Shs Outstand | 306.5M | Perf Week | 9.56% |
| Market Cap | 4.16B | Forward P/E | - | EPS next Y | -9.58% | Insider Trans | - | Shs Float | 253.6M | Perf Month | -7.83% |
| Enterprise Value | 3.73B | PEG | - | EPS next Q | -0.18 | Inst Own | 36.03% | Short Float | 12.2% | Perf Quarter | 138.03% |
| Income | -0.16B | P/S | 62.83 | EPS this Y | -35.44% | Inst Trans | -6.06% | Short Ratio | 4.76 | Perf Half Y | 208.41% |
| Sales | 0.07B | P/B | 4.39 | EPS next 5Y | -18.95% | ROA | -12.15% | Short Interest | 30.93M | Perf YTD | 275.15% |
| Book/sh | 2.92 | P/C | 7.36 | EPS past 3/5Y | - | ROE | -17.3% | 52W High | -14.55% ($15.02) | Perf Year | 122.36% |
| Cash/sh | 1.74 | P/FCF | - | Sales past 3/5Y | -46.31% -20.27% | ROIC | -16.05% | 52W Low | 367.4% ($2.74) | Perf 3Y | 228.13% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 2.49% | Gross Margin | 50.74% | Volatility(W/M) | 7.47% 6.53% | Perf 5Y | -16.53% |
| Dividend TTM | - | EV/Sales | 56.34 | Sales Y/Y TTM | 101.28% | Oper. Margin | -340.25% | ATR (14) | 0.81 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 12.63 | EPS Q/Q | -55.98% | Profit Margin | -248.83% | RSI (14) | 55 | Recom | 1.15 |
| Dividend Gr. 3/5Y | - | Current Ratio | 12.77 | Sales Q/Q | -76.29% | SMA20 | 1.57% ($12.63) | Beta | 1.58 | Target Price | $16.82 |
| Payout | - | Debt/Eq | 0.15 | Earnings | 2026/11/9 | SMA50 | 5.16% ($12.2) | Rel Volume | 0.53 | Prev Close | $12.08 |
| Employees | 562 | LT Debt/Eq | 0.15 | EPS/Sales Surpr. | -9.76% -48.39% | SMA200 | 90.86% ($6.72) | Avg Volume(3M) | 6.50M | Price | $12.83 |
| IPO | 2020/12/11 | Option/Short | Yes/Yes | Trades | 14006 | Volume | 3,460,483 | Change | 6.21% |
🔬 A US- and Canada-based biotech company that operates an antibody discovery platform. By combining artificial intelligence with high-throughput screening technology, the platform is used to discover therapeutic antibodies, and the company runs a model that pairs pharmaceutical partnerships with its own proprietary pipeline. It has established itself as a differentiated biotech by integrating its antibody discovery platform with its pipeline.
Over the past 1 year, on the higher side
15% below its 1-year high.
Traded less than usual. That is 53% of its average volume.
Next earnings report: November 9
12 days to go.
ABCL has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -35.4% this year.
Tap to view numbers
Relative to sales, it looks expensive
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $6,283. Peers typically go for $1,648. Compared with its own 1-year average, it is 12% cheaper now.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -16.5%. The S&P 500 did +70% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 36.0%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #59 of 594 in the industry
Based on market cap of $4B.
EWTX#57 Edgewise Therapeutics Inc $4B PER - 
LEGN#58 Legend Biotech Corp ADR $4B PER - ABCL#59 AbCellera Biologics Inc $4B PER - 
RLAY#60 Relay Therapeutics Inc $4B PER - 
ARQT#61 Arcutis Biotherapeutics Inc $4B PER 153.0 
FAQ
What kind of company is ABCL?
ABCL belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of ABCL?
The market cap of ABCL is approximately $4.2B, ranking 1,506 within its sector.
What is the 52-week high and low for ABCL?
ABCL has recorded a 52-week high of $15.02 and a low of $2.74.
